



Anatara announces successful piglet study

Key highlight

- **Under the conditions of this proof-of-concept study and given the experimental outcomes, BONIFF could be considered as a replacement for a non-physiological level of ZnO with commercial levels of additives in a semi-moist extruded creep (SMEC) piglet diet.**

MELBOURNE, 6 August 2021: Anatara Lifesciences (ASX: ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to announce the successful completion of a challenge study in weaner piglets with its recently developed bromelain-based formulation (BONIFF).

To address weaner piglet scour, which is estimated to cost the Australian pig industry more than \$7 million per year¹, Anatara and Ridley initiated a weaner piglet enterotoxigenic *E. coli* (ETEC) challenge study, utilising Anatara's bromelain-based formulation (BONIFF). The study was conducted by Murdoch University, with funding from the Australasian Pork Research Institute Ltd.

Detach® is a commercial product registered in Australia (Anatara Lifesciences) for the prevention of post-weaning diarrhoea (PWD) in pigs and has been shown to reduce PWD and provide similar protection to antimicrobial agents including ZnO (Holyoake and Mynott, 2017) as well as reduce antimicrobial resistance (AMR) (Collins and Bowring, 2017). However, Detach® is a paste requiring labour and effort to deliver the compound by drenching. BONIFF is a revised formulation that is applied to dry feed for piglets after weaning, reducing labour input and simplifying the entire process. Semi-moist extruded creep feed (SMEC) has previously been shown to improve performance after weaning (Pork Cooperative Research Centre Final Report 2009). BONIFF in combination with SMEC as a feed has demonstrated the potential to (a) reduce PWD caused by ETEC and (b) improve performance in the post-weaning period.

The standard diet and the BONIFF-SMEC diets did not contain a pharmacological level of ZnO nor a commercial level of organic acid products (organic acids for manufacturing purposes only were added), whereas the SMEC diet alone (Treatment 5) contained commercially relevant levels of ZnO, organic acids and phytogenic compounds.

In general, although indicating only a statistical trend ($P > 0.2$), pigs fed the BONIFF-SMEC diets and the SMEC (only) diet were heavier, by ~6-11% respectively, at the end of the experiment compared to pigs fed the Standard diet, and not different to each other. This difference appeared to be caused by a significantly faster growth rate particularly in days 7-11 and days 12-13 after weaning that corresponded to a (numerically) higher daily feed intake in those periods. These periods coincided with the immediate time after ETEC inoculation and the change on day 11 to the common weaner

Anatara Lifesciences Limited

Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anatara.com | Website anataralifesciences.com



diet, respectively. Intriguingly, days 7-11 was the period where pigs fed BONIFF-SMEC and SMEC diet alone (Treatment 5) generally showed more loose faeces and a higher diarrhoea index and received more medications.

In these circumstances the product combination (in the case of BONIFF-SMEC) performance was not only able to be maintained but was greater than the Standard diet (i.e. not SMEC). For clarity, none of these diets contained commercially relevant levels of antimicrobial compounds.

The growth performance data also demonstrated that pigs fed the BONIFF-SMEC diet performed equally, both with and without ETEC inoculation, to pigs fed the SMEC diet alone (Treatment 5) that comprised a pharmacological level of ZnO and levels of organic acids and phytogenics seen commercially, to assist in transitioning pigs in the post-weaning period. This suggests that at least under the conditions of this experiment, BONIFF could be considered as a replacement for these additives.

CEO Steve Lydeamore commented, "Anatara is pleased to have met its aim to develop alternative administration options and proof of concept in another species for its bromelain-based products. Anatara's animal health portfolio now includes Detach®, ANR-pf for poultry and, BONIFF, an in-feed formulation for weaner piglets."

Detach® is an APVMA approved, non-antibiotic approach to aid in the control of diarrheal disease (known as "scour" which can be a debilitating and, in some cases, life-threatening condition). It is protected by the recently announced patent number AU2019204496 entitled "Antidiarrhoea formulation which avoids antimicrobial resistance".

In February 2021, Anatara announced the successful completion of the poultry challenge trial "Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges". ANR-pf is Anatara's proprietary enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method on-farm even when stock illness is a concern.

CEO Steve Lydeamore added, "With this successful piglet study in hand, commercialisation discussions will now commence with pig producers and animal feed/nutrition companies."



Post-weaning diarrhoea (PWD) is one of the major problems in the Australian (and world) swine industries causing economic losses and decreases in the performance and survival of weaned pigs. The diarrhoea is caused by strains (types) of enterotoxigenic *E. coli* (ETEC) that adhere to receptors on the enterocytes and colonise the surface of the small intestine. The enterotoxins produced enhance the net secretion of water (i.e., into the intestines) to cause diarrhoea (Pluske et al., 2018). Traditionally antibiotics have been used for the prophylactic treatment of these pathogenic bacteria. However, rising concerns about antimicrobial resistance (AMR) caused by feeding antibiotics or other compounds such as zinc oxide (ZnO) and the ban of antibiotic-based growth promoters (AGP) and prophylactic antibiotic use in a growing number of countries has compelled the search for alternatives to in-feed antibiotics (Pluske, 2013). The use of medicinal zinc oxide (ZnO) to prevent diarrhoea post-weaning will be banned in the EU from 2022. (European Medicines Agency 2017). The issue of AMR is growing worldwide and therefore in the pork industry (Pollock et al., 2020), alternatives to traditional preventative compounds such as ZnO and AGP are urgently needed to maintain pig health and welfare.

¹ <https://www.business.qld.gov.au/industries/farms-fishing-forestry/agriculture/livestock/animal-welfare/pests-diseasesdisorders/piglet-scours>

Collins A.M. and Bowring B.G. (2017). Reduced antimicrobial resistance in weaner pigs treated with Detach® following natural challenge with F4 *Escherichia coli*. *Animal Production Science* 57:2491.

European Medicines Agency (16 March 2017): <https://www.ema.europa.eu/en/medicines/veterinary/referrals/zinc-oxide>

Holyoake P.K. and Mynott T.L. (2017). A comparative study of the efficacy of Detach® versus zinc oxide to control post weaning diarrhoea in pigs. *Animal Production Science* 57:2503.

Pluske, J.R. (2013). Feed- and feed additives-related aspects of gut health and development in weanling pigs. *Journal of Animal Science and Biotechnology* 4:1.

Pluske, J.R., Turpin, D.L. and Kim, J.C. (2018). Gastrointestinal tract (gut) health in the young pig. *Animal Nutrition* 4:187-196.

Pollock, J., Muwonge, A., Hutchings M.R., Mainda, G., Bronsvort, B.M., Gally, D.L. and Corbishley, A. (2020). Resistance to change: AMR gene dynamics on a commercial pig farm with high antimicrobial usage. *Scientific Reports* 10:1708.

Pork Cooperative Research Centre; Final Report (2009) (PROJECT 2B-106: DEVELOPMENT OF SEMI-MOIST EXTRUDED CREEP FEEDS TO PROMOTE GASTRO- INTESTINAL TRACT DEVELOPMENT, FEED INTAKE AND SUBSEQUENT WEANING WEIGHTS).

Anatara Lifesciences Limited
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anatara.com | Website anataralifesciences.com



For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anantara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anantara.com	Eric Kuret Market Eye +61 (0) 417 311 335 eric.kuret@marketeye.com.au

About Anantara Lifesciences Ltd

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for animal and human health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anantara Lifesciences Limited
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anantara.com | Website anataralifesciences.com

